RESUMO
Memsorb™ (DMF Medical, Halifax, Canada) is a novel device based upon membrane oxygenator technology designed to eliminate CO2 from exhaled gas when using a circle anesthesia circuit. Exhaled gases pass through semipermeable hollow fibers and sweep gas flowing through these fibers creates a diffusion gradient for CO2 removal. In vivo Memsorb™ performance was tested during target-controlled closed-circuit anesthesia (TCCCA) with desflurane in O2/air using a Zeus IE® anesthesia workstation (Dräger, Lübeck, Germany). Clinical care protocols for using this novel device were guided by in vitro performance results from a prior study (submitted simultaneously). After IRB approval, written informed consent was obtained from 10 ASA PS I-III patients undergoing robot-assisted radical prostatectomy. TCCCA targets were 39% inspired O2 concentration (FIO2) and 5.0% end-expired desflurane concentration (FETdes). Minute ventilation (MV) was adjusted to maintain 4.5-6.0% FETCO2. The O2/air (40% O2) sweep flow into the Memsorb™ was manually adjusted in an attempt to keep inspired CO2 concentration (FICO2) ≤ 0.8%. The following data were collected: FIO2, FETdes, FICO2, FETCO2, MV, fresh gas flow (FGF, O2 and air), sweep flow, and cumulative desflurane usage (Vdes). Vdes of the Zeus IE®-Memsorb™ combination was compared with historical Vdes observed in a previous study when soda lime (DrägerSorb 800 +) was used. Results are reported as median and inter-quartiles. A combination of manually adjusting sweep flow (26 [21,27] L/min) and MV sufficed to maintain FICO2 ≤ 0.8% and FETCO2 ≤ 6.0%, except in one patient in whom the target Zeus IE® FGF had to be increased to 0.7 L/min for 6 min. FIO2 and FETdes were maintained close to their targets. Zeus IE® FGF after 5 min was 0 [0,0] mL/min. Average Vdes after 50 min was higher with Memsorb™ (20.3 mL) compared to historical soda lime canister data (12.3 mL). During target-controlled closed-circuit anesthesia in patients undergoing robot-assisted radical prostatectomy, the Memsorb™ maintained FICO2 ≤ 0.8% and FETCO2 ≤ 6.0%, and FIO2 remained close to target. Modest amounts of desflurane were lost with the use of the Memsorb™. The need for adjustments of sweep flow, minute ventilation, and occasionally Zeus IE® FGF indicates that the Memsorb™ system should preferentially be integrated into an automated closed-loop system.
Assuntos
Anestesia com Circuito Fechado , Anestésicos Inalatórios , Masculino , Humanos , Desflurano , Dióxido de Carbono , Hidróxido de SódioRESUMO
Soda lime-based CO2 absorbents are safe, but not ideal for reasons of ecology, economy, and dust formation. The Memsorb™ is a novel CO2 removal device that uses cardiopulmonary bypass oxygenator technology instead: a sweep gas passes through semipermeable hollow fibers, adding or removing gas from the circle breathing system. We studied the in vitro performance of a prototype Memsorb™ used with a Zeus IE® anesthesia machine when administering sevoflurane and desflurane in O2/air mixtures. The Zeus IE® equipped with Memsorb™ ventilated a 2L breathing bag with a CO2 inflow port in its tip. CO2 kinetics were studied by using different combinations of CO2 inflow (VCO2), Memsorb™ sweep gas flow, and Zeus IE® fresh gas flow (FGF) and ventilator settings. More specifically, it was determined under what circumstances the inspired CO2 concentration (FICO2) could be kept < 0.5%. O2 kinetics were studied by measuring the inspired O2 concentration (FIO2) resulting from different combinations of Memsorb™ sweep gas flow and O2 concentrations, and Zeus IE® FGFs and O2 concentrations. Memsorb™'s sevoflurane and desflurane waste was determined by measuring their injection rates during target-controlled closed-circuit anesthesia (TCCCA), and were compared to historical controls when using a soda lime absorbent (Draegersorb 800+) under identical conditions. With 160 mL/min VCO2 and 5 L/min minute ventilation (MV), lowering the sweep gas flow at any fixed Zeus IE® FGF increased FICO2 in a non-linear manner. Sweep gas flow adjustments kept FICO2 < 0.5% over the entire Zeus IE® FGF range tested with VCO2 up to 280 mL/min; tidal volume and respiratory rate affected the required sweep gas flow. At 10 L/min MV and low FGF (< 1.5 L/min), even a maximum sweep flow of 43 L/min was unable to keep FICO2 ≤ 0.5%. When the O2 concentration in the Zeus IE® FGF and the Memsorb™ sweep gas flow differed, FIO2 drifted towards the sweep gas O2 concentration, and more so as FGF was lowered; this effect was absent once FGF > minute ventilation. During sevoflurane and desflurane TCCCA, the Zeus IE® FGF remained zero while agent usage per % end-expired agent increased with increasing end-expired target agent concentrations and with a higher target FIO2. Agent waste during target-controlled delivery was higher with Memsorb™ than with the soda lime product, with the difference remaining almost constant over the FGF range studied. With a 5 L/min MV, Memsorb™ successfully removes CO2 with inflow rates up to 240 mL/min if an FICO2 of 0.5% is accepted, but at 10 L/min MV and low FGF (< 1.5 L/min), even a maximum sweep flow of 43 L/min was unable to keep FICO2 ≤ 0.5%. To avoid FIO2 deviating substantially from the O2 concentration in the fresh gas, the O2 concentration in the fresh gas and sweep gas should match. Compared to the use of Ca(OH)2 based CO2 absorbent, inhaled agent waste is increased. The device is most likely to find its use integrated in closed loop systems.
Assuntos
Anestesia com Circuito Fechado , Anestésicos Inalatórios , Humanos , Sevoflurano , Dióxido de Carbono , DesfluranoRESUMO
Data directly comparing CO2 absorbents tested in identical and clinically relevant conditions are scarce or non-existent. We therefore tested and compared the efficiency of 16 different brands of Ca(OH)2 based CO2 absorbents used as loose fill or a cartridge in a refillable canister under identical low flow conditions. CO2 absorbents efficiency was tested by flowing 160 mL/min CO2 into the tip of a 2 L balloon that was ventilated with an ADU anesthesia machine (GE, Madison, WI, USA) with a tidal volume of 500 mL and a respiratory rate of 10/min while running an O2/air FGF of 300 mL/min. After the 1020 mL refillable container was filled with a known volume of CO2 absorbent (derived from weighing the initial canister content and the product's density), the time for the inspired CO2 concentration (FICO2) to rise to 0.5% was measured. This test was repeated 4 times for each product. Because the two SpiraLith Ca® products (one with and one without indicator) are delivered as a cartridge, they had to be tested using their proprietary canister. The time (min) for FICO2 to reach 0.5% was normalized to 100 mL of product, and defined as the efficiency, which was compared amongst the different brands using ANOVA. Efficiency ranged from 50 to 100 min per 100 mL of product, and increased with increasing NaOH content (a catalyst), the exception being SpiraLith Ca® cartridge with color indicator (performing as well as the most efficient granular products) and the SpiraLith Ca® cartridge without color indicator (outperforming all others). Results indicated a spherical or bullet shape is less efficient in absorbing CO2 than broken fragments or cylinders, which in turn is less efficient than a hemispherical (disc) shape, which is in turn less efficient than a solid cartridge with a molded channel geometry. The efficiency of Ca(OH)2 based CO2 absorbent differs up to 100% on a volume basis. Macroscopic arrangement (cylindrical wrap with preformed channels versus granules), chemical composition (NaOH content), and granular shape all affect efficiency per volume of product. The data can be used to compare costs of the different products.
Assuntos
Anestesiologia/instrumentação , Dióxido de Carbono/química , Anestesia/métodos , Anestesiologia/métodos , Hidróxido de Cálcio , Desenho de Equipamento , Reprodutibilidade dos Testes , Hidróxido de Sódio , Fatores de TempoRESUMO
Low fresh gas flows (FGFs) decrease the use of anesthetic gases, but increase CO2 absorbent usage. CO2 absorbent usage remains poorly quantified. The goal of this study is to determine canister life of 8 commercially available CO2 absorbent prepacks with the Zeus®. Pre-packed CO2 canisters of 8 different brands were tested in vitro: Amsorb Plus, Spherasorb, LoFloSorb, LithoLyme, SpiraLith, SpheraSorb, Drägersorb 800+, Drägersorb Free, and CO2ntrol. CO2 (160 mL min- 1) flowed into the tip of a 2 L breathing bag that was ventilated with a tidal volume of 500 mL, a respiratory rate of 10/min, and an I:E ratio of 1:1 using the controlled mechanical ventilation mode of the Zeus® (Dräger, Lubeck, Germany). In part I, canister life of 5 canisters each of 2 different lots of each brand was determined with a 350 mL min- 1 FGF. Canister life is the time it takes for the inspired CO2 concentration (FICO2) to rise to 0.5%. In part II, canister life was measured accross a FGF range of 0.25 to 4 L min- 1 for Drägersorb 800+ (2 lots) and SpiraLith (1 lot). In part III, the calculated canister life per 100 g fresh granule content of the different brands was compared between the Zeus and (previously published data for) the Aisys. In vitro canister life of prefilled CO2 absorber canisters differed between brands, and depended on the amount of CO2 absorbent and chemical composition. Canister life expressed as FCU0.5 (the fraction of the canister used per hour) was proportional to FGF over 0.2-2 L min-1 range only, but was non-linear with higher FGF: FCU0.5 was larger than expected with FGF > 2 L min-1, and even with FGF > minute ventilation FCU0.5 did not become zero, indicating some CO2 was being absorbed. Canister life on a per weight basis of the same brand is higher with the Zeus than the Aisys. Canister life of prefilled CO2 absorber canisters differs between brands. The FCU0.5-FGF relationship is not linear across the entire FGF range. Canister life of prepacks of the same brand for the Zeus and Aisys differs, the exact etiology of which is probably multifactorial, and may include differences in the absolute amount of absorbent and different rebreathing characteristics of the machines.
Assuntos
Anestesia por Inalação/instrumentação , Anestésicos Inalatórios , Dióxido de Carbono/isolamento & purificação , Adsorção , Anestesia por Inalação/economia , Anestesia por Inalação/métodos , Cloreto de Cálcio , Hidróxido de Cálcio , Custos e Análise de Custo , Humanos , Técnicas In Vitro , Hidróxido de SódioRESUMO
AGC® (Automatic Gas Control) is the FLOW-i's automated low flow tool (Maquet, Solna, Sweden) that target controls the inspired O2 (FIO2) and end-expired desflurane concentration (FAdes) while (by design) exponentially decreasing fresh gas flow (FGF) during wash-in to a maintenance default FGF of 300 mL min-1. It also offers a choice of wash-in speeds for the inhaled agents. We examined AGC performance and hypothesized that the use of lower wash-in speeds and N2O both reduce desflurane usage (Vdes). After obtaining IRB approval and patient consent, 78 ASA I-II patients undergoing abdominal surgery were randomly assigned to 1 of 6 groups (n = 13 each), depending on carrier gas (O2/air or O2/N2O) and wash-in speed (AGC speed 2, 4, or 6) of desflurane, resulting in groups air/2, air/4, air/6, N2O/2, N2O/4, and N2O/6. The target for FIO2 was set at 35%, while the FAdes target was selected so that the AGC displayed 1.3 MAC (corrected for the additive affect of N2O if used). AGC was activated upon starting mechanical ventilation. Varvel's criteria were used to describe performance of achieving the targets. Patient demographics, end-expired N2O concentration, MAC, FGF, and Vdes were compared using ANOVA. Data are presented as mean ± standard deviation, except for Varvel's criteria (median ± quartiles). Patient demographics did not differ among the groups. Median performance error was -2-0% for FIO2 and -3-1% for FAdes; median absolute performance error was 1-2% for FIO2 and 0-3% for FAdes. MAC increased faster in N2O groups, but total MAC decreased 0.1-0.25 MAC below that in the O2/air groups after 60 min. The effect of wash-in speed on Vdes faded over time. N2O decreased Vdes by 62%. AGC performance for O2 and desflurane targeting is excellent. After 1 h, the wash-in speeds tested are unlikely to affect desflurane usage. N2O usage decreases Vdes proportionally with its reduction in FAtdes.
Assuntos
Anestesia por Inalação/instrumentação , Anestesia por Inalação/métodos , Anestésicos Inalatórios/administração & dosagem , Desflurano/administração & dosagem , Óxido Nitroso/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Anestesia por Inalação/estatística & dados numéricos , Anestésicos Inalatórios/farmacocinética , Desflurano/farmacocinética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Monitorização Intraoperatória , Oxigênio/administração & dosagemRESUMO
BACKGROUND: Limited studies examined effects of pneumoperiotneum during robot-assisted radical prostatectomy (RARP) and with AirSeal. The aim of this study was to assess the effect on hemodynamics of a lower pressure pneumoperitoneum (8 mmHg) with AirSeal, during RARP in steep Trendelenburg 45° (ST). MATERIALS AND METHODS: This is an institutional review board-approved, prospective, interventional, single-center study including patients treated with RARP at OLV Hospital by one extremely experienced surgeon (July 2015-February 2016). Intraoperative monitoring included: arterial pressure, central venous pressure, cardiac output, heart rate, stroke volume, systemic vascular resistance, intrathoracic pressure, airways pressures, left ventricular end-diastolic and end-systolic areas/volumes and ejection fraction, by transesophageal echocardiography, an esophageal catheter, and FloTrac/Vigileo system. Measurements were performed after induction of anesthesia with patient in horizontal (T0), 5 minutes after 8 mmHg pneumoperitoneum (TP), 5 minutes after ST (TT1) and every 30 minutes thereafter until the end of surgery (TH). Parameters modification at the prespecified times was assessed by Wilcoxon and Friedman tests, as appropriate. All analyses were performed by SPSS v. 23.0. RESULTS: A total of 53 consecutive patients were enrolled. The mean patients age was 62.6 ± 6.9 years. Comorbidity was relatively limited (51% with Charlson Comorbidity Index as low as 0). Despite the ST, working always at 8 mmHg with AirSeal, only central venous pressure and mean airways pressure showed a statistically significant variation during the operative time. Although other significant hemodynamic/respiratory changes were observed adding pneumoperitoneum and then ST, all variables remained always within limits safely manageable by anesthesiologists. CONCLUSION: The combination of ST, lower pressure pneumoperitoneum and extreme surgeon's experience enables to safely perform RARP.
Assuntos
Pneumoperitônio/epidemiologia , Prostatectomia/instrumentação , Procedimentos Cirúrgicos Robóticos/efeitos adversos , Idoso , Pressão Sanguínea , Hemodinâmica , Humanos , Masculino , Pessoa de Meia-Idade , Monitorização Intraoperatória , Duração da Cirurgia , Pneumoperitônio/etiologia , Estudos Prospectivos , Prostatectomia/efeitos adversosRESUMO
This review re-examines existing pharmacokinetic and pharmacodynamic concepts of inhaled anaesthetics. After showing where uptake is hidden in the classic FA/FI curve, it is argued that target-controlled delivery of inhaled agents warrants a different interpretation of the factors affecting this curve (cardiac output, ventilation and blood/gas partition coefficient). Blood/gas partition coefficients of modern agents may be less important clinically than generally assumed. The partial pressure cascade from delivered to inspired to end-expired is re-examined to better understand the effect of rebreathing during low-flow anaesthesia, including the possibility of developing a hypoxic inspired mixture despite existing machine standards. Inhaled agents are easy to administer because they are transferred according to partial pressure gradients. In addition, the narrow dose-response curves for the three end points of general anaesthesia (loss of response to verbal command, immobility and autonomic reflex control) allow the clinical use of MACawake, MAC and MACBAR to determine depth of anaesthesia. Opioids differentially affect these clinical effects of inhaled agents. The effect of ventilation-perfusion relationships on gas uptake is discussed, and it is shown how moving beyond Riley's useful but simplistic model allows us to better understand both the concept and the magnitude of the second gas effect of nitrous oxide. It is argued that nitrous oxide remains a clinically useful drug. We hope to bring old (but ignored) and new (but potentially overlooked) information into the educational and clinical arenas to stimulate discussion among clinicians and researchers. We should not let technology pass by our all too engrained older concepts.
Assuntos
Anestesia por Inalação/métodos , Anestésicos Inalatórios/administração & dosagem , Óxido Nitroso/administração & dosagem , Analgésicos Opioides/administração & dosagem , Anestesia com Circuito Fechado/métodos , Anestesia com Circuito Fechado/tendências , Anestesia por Inalação/tendências , Gasometria/métodos , Humanos , Pressão ParcialRESUMO
Current hypoxic guards systems fail to maintain the inspired O2 concentration (FIO2) ≥ 21 % across the entire fresh gas flow (FGF) range when a second carrier gas is used (N2O or air). We examined the performance of the Maquet O2 Guard(®), a smart hypoxic guard that increases O2 delivery if an inspired hypoxic mixture is formed. After obtaining IRB approval and informed consent, 12 ASA I-II patients were enrolled. During anesthesia with sevoflurane in O2/air, the O2 Guard(®) was tested by administering O2/air at the following delivered hypoxic guard limits [expressed as (total FGF in L min(-1); FDO2 in %)] for 4 min each: [0.3;67], [0.4;50], [0.6;34], [0.8;25], [1.0;21], [1.2;21], [1.5;21], [2;21], [3;21], and [5;21]. The following data were collected: (1) time from FIO2 = 30 to 20 %; (2) time from FIO2 = 20 % to O2 Guard(®) activation; (3) time from O2 Guard(®) activation to FIO2 = 25 %; (4) FGF and FDO2 used by the O2 Guard. If SpO2 was <90 % for 10 s or longer at any time, the patient was excluded. Three patients were excluded for low SpO2. The incidence of FIO2 < 21 % was 100 % within the 1-2 L min(-1) FGF range. The O2 Guard(®) was activated within 20 s after FIO2 became 20 %, except in one patient where FIO2 oscillated between 20 and 21 %. FDO2 was increased to 60 % and FGF to 1 L min(-1) (the latter only if it was lower than 1 L min(-1) prior to activation of the O2 Guard). FIO2 increased to 25 % within 55 s after O2 Guard activation in all patients. The O2 Guard(®), an active inspired hypoxic guard, rapidly reverses and limits the duration of inspired hypoxic episodes when the delivered hypoxic guard fails to do so.
Assuntos
Anestesia por Inalação/instrumentação , Anestésicos Inalatórios/administração & dosagem , Hipóxia/prevenção & controle , Monitorização Intraoperatória/instrumentação , Óxido Nitroso/administração & dosagem , Oxigênio/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Anestesia por Inalação/métodos , Alarmes Clínicos , Desenho de Equipamento , Análise de Falha de Equipamento , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Monitorização Intraoperatória/métodos , Óxido Nitroso/análise , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
The FLOW-i anesthesia machine (Maquet, Solna, Sweden) can be equipped with automated gas control (AGC), an automated low flow tool with target control of the inspired oxygen concentration (FIO2) and end-expired concentration (FA) of a potent inhaled anesthetic. We examined the performance and quantitative aspects of the AGC. After IRB approval and individual informed consent, anesthesia in 24 ASA I-II patients undergoing abdominal or gynecological surgery was maintained with sevoflurane in O2/air with a target FIO2 of 40 % and a target sevoflurane FA (FAsevo) of 2.0 %. The AGC tool also allows the user to select 1 out of 9 different speeds with which the target FAsevo can be reached (with 9 being the fastest speed). Eight patients each were randomly assigned to speed 2, 4, and 6 (= group 2, group 4, and group 6, respectively); these three speeds were chosen arbitrarily. AGC was activated immediately after securing the airway, which defined the start of the study, and the study ended 60 min later. The following parameters were compared among the three groups: age, height, weight, FIO2, FAsevo, BIS values, heart rate, mean arterial blood pressure, fresh gas flow, and sevoflurane usage. Agent usage as reported by the FLOW-i was compared among the three groups. Patient demographics and maintenance FGF did not differ among groups. A very short-lived very high FGF (≈20 L min(-1) for 8-12 s) ensured that the target FIO2 was attained within 1-2 min in all patients. FAsevo was 1.8 % after 15, 10, and 6 min, and 1.9 % after 30, 20 and 15 min in groups 2, 4, and 6, respectively. Blood pressure, heart rate, and BIS values did not differ among the three groups. BIS values remained acceptable in all patients, even with the slowest speed. Cumulative agent usage differed among all three groups between 2 and 30 min (lower with the lower speed), and between group 2 and 6 between 35 and 60 min. AGC combines an exponentially decreasing FGF pattern with a choice of ramp functions for the end-expired target concentration of the inhaled anesthetic. Consequently, both FGF and the choice of speed become factors that influence agent usage. After 15 min, a 300 mL min(-1) maintenance FGF reduces agent usage to near closed-circuit conditions. This new addition to our automated low flow armamentarium helps to reduce anesthetic waste, cost, and pollution, while minimizing the ergonomic burden of low flow anesthesia.
Assuntos
Anestesia com Circuito Fechado/instrumentação , Idoso , Anestesia com Circuito Fechado/estatística & dados numéricos , Anestésicos Inalatórios/administração & dosagem , Automação , Feminino , Humanos , Masculino , Éteres Metílicos/administração & dosagem , Pessoa de Meia-Idade , Monitorização Intraoperatória , SevofluranoRESUMO
Low flow anesthesia increases the use of CO2 absorbents, but independent data that compare canister life of the newest CO2 absorbents are scarce. Seven different pre-packed CO2 canisters were tested in vitro: Amsorb Plus, Spherasorb, LoFloSorb, Medisorb, Medisorb EF, LithoLyme, and SpiraLith. CO2 (160 mL min(-1)) flowed into the tip of a 2 L breathing bag that was ventilated with a tidal volume of 500 mL, a respiratory rate of 10/min, and an I:E ratio of 1:1 using the controlled mechanical ventilation mode of the Aisys (®) (GE, Madison, WI, USA). In part I, canister life of each brand (all of the same lot) was tested with 12 different fresh gas flows (FGF) ranging from 0.25 to 4 L min(-1). In part II, canister life of six canisters each of two different lots of each brand were tested with a 350 mL min(-1) FGF. Canister life is presented as "FCU", fractional canister usage, the fraction of a canister used per hour, and is defined for the inspired CO2 concentration (FICO2) that denotes exhaustion. In part III, canister life per 100 g fresh granule content was calculated. FCU decreased linearly with increasing FGF. The relative position of the FCU-FGF curves of the different brands depends on the FICO2 threshold because the exhaustion rate (the rate of rise once FICO2 starts to increase) differs among the brands. Intra-lot variability was 18 % or less. The different prepacks can be ranked according their efficiency (least to most efficient) as follows: Amsorb Plus = Medisorb EF < LoFloSorb < Medisorb = Spherasorb = LithoLyme < SpiraLith (all for an FICO2 threshold = 0.5 %). Canister life per 100 g fresh granule content is almost twice as long when LiOH is used as the primary absorbent. The most important factors that determine canister life of prepacks in a circle breathing system are the chemical composition of the canister, the absolute amount of absorbent present in the canister, and the FICO2 replacement threshold. The use of the fractional canister usage allows cost comparisons among different prepacks. Results should not be extrapolated to prepacks that fit onto other anesthesia machines.
Assuntos
Anestesia com Circuito Fechado/instrumentação , Dióxido de Carbono/química , Dióxido de Carbono/isolamento & purificação , Equipamentos Descartáveis , Ultrafiltração/instrumentação , Absorção Fisico-Química , Cloreto de Cálcio/química , Hidróxido de Cálcio/química , Desenho de Equipamento , Análise de Falha de Equipamento , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Automated low flow anesthesia machines report how much inhaled anesthetic agent has been used for each anesthetic. We compared these reported values with the amount of agent that had disappeared by weighing the vaporizer/injectors before and after each anesthetic. The vaporizers/injectors of the Aisys, Zeus and FLOW-i were weighed with a high precision weighing scale before and after anesthesia with either desflurane in O2/air or sevoflurane in O2/N2O. These values were compared with the values reported by the cumulative agent use display tools of the respective anesthesia machines using a linear curve fit. Twenty-five measurements were performed in each group, except for the sevoflurane data with the Aisys that were available from another study (87 pairs). We also determined the amount lost by inserting and removing the vaporizers/injectors or by performing a machine checkout, corrected the measured amounts for these artifacts and repeated the linear fits. The average amount of sevoflurane and desflurane wasted by inserting and removing the cassette for the Aisys, Zeus, and FLOW-i were 0.21, 0.12, and 0.04 mL and 0.12, 0.61, and 1.13 mL liquid agent, respectively. The average amount of sevoflurane and desflurane wasted by the machine checkout with the Aisys, Zeus, and FLOW-i were 1.78, 0.21, and 1.67 mL and 2.39, 0.67, and 4.19 mL, respectively. Performance error of the displayed amount of agent use remained within 10 % of the weighed amount, expect for amounts less than 3 mL sevofurane with the FLOW-i and less than 20 mL desflurane with the Aisys and FLOW-i. Cumulative agent usage displayed by the Aisys, Zeus, and FLOW-i is within 10 % of the measured consumption, except for low consumption cases (<3 mL sevoflurane, <20 mL desflurane). The differences may be due to either measurement error or cumulative agent display error. The current results can help the researchers decide whether the displayed amounts are accurate enough for their study purposes. The extent to which these discrepancies differ between different units of the same machine remains unstudied.
Assuntos
Anestesia com Circuito Fechado/métodos , Anestesiologia/métodos , Anestésicos Inalatórios/administração & dosagem , Artefatos , Desflurano , Sistemas de Liberação de Medicamentos , Humanos , Isoflurano/administração & dosagem , Isoflurano/análogos & derivados , Modelos Lineares , Éteres Metílicos/administração & dosagem , Nebulizadores e Vaporizadores , Reprodutibilidade dos Testes , Sevoflurano , Processamento de Sinais Assistido por ComputadorRESUMO
STUDY OBJECTIVE: To determine if the previously described single-step O(2)/N(2)O fresh gas flow (FGF) sequence could be combined with a simple desflurane vaporizer (F(D)) sequence to maintain the end-expired desflurane (F(A)des) at 4.5% with the anesthesia delivery unit machine (ADU Anesthesia Machine(R); General Electric, Helsinki, Finland). DESIGN: Prospective randomized clinical study. SETTING: Onze Lieve Vrouw Hospital, Aalst, Belgium, a large teaching hospital. PATIENTS: 42 ASA physical status I and II patients requiring general endotracheal anesthesia and controlled mechanical ventilation. INTERVENTIONS: In 18 patients undergoing general anesthesia with controlled mechanical ventilation, F(D) was determined to maintain F(A)des at 4.5% with O(2)/N(2)O FGF of two and 4 L per minute for three minutes and 0.3 and 0.4 L per minute thereafter. Using the same FGF sequence, we prospectively tested the F(D) schedule that approached this observed F(D) pattern with the fewest possible adjustments in another 24 patients. MAIN RESULTS: F(D) of 6.5% for 15 minutes followed by 5.5% thereafter approximated the observed F(D) course well. When it was prospectively tested, the median (25th, 75th percentiles) performance error was -1% (-5.1%, 5.2%); absolute performance error, 7.1% (3.9%, 9.5%); divergence, -6.6% per hour (23.1%, 3.1%/h); and wobble, 2.2% (1.8%, 3.2%). Because F(A)des increased above 4.9%, F(D) was decreased in 5 patients after 23 minutes (0.5% decrement once or twice); in two patients, F(D) was temporarily increased. In one patient, FGF was temporarily increased because the bellows volume became insufficient. CONCLUSIONS: One O(2)/N(2)O rotameter FGF setting change from 6 to 0.7 L per minute after three minutes and one desflurane F(D) change from 6.5% to 5.5% after 15 minutes maintained anesthetic gas concentrations within predictable and clinically acceptable limits during the first 20 minutes.
Assuntos
Anestesia por Inalação/métodos , Anestésicos Inalatórios/administração & dosagem , Isoflurano/análogos & derivados , Óxido Nitroso/administração & dosagem , Desflurano , Feminino , Humanos , Isoflurano/administração & dosagem , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Respiração/efeitos dos fármacos , Respiração Artificial/métodos , Resultado do TratamentoRESUMO
BACKGROUND: The Zeus® (Dräger, Lübeck, Germany), an automated closed-circuit anesthesia machine, uses high fresh gas flows (FGF) to wash-in the circuit and the lungs, and intermittently flushes the system to remove unwanted N2. We hypothesized this could increase desflurane consumption to such an extent that agent consumption might become higher than with a conventional anesthesia machine (Anesthesia Delivery Unit [ADU®], GE, Helsinki, Finland) used with a previously derived desflurane-O2-N2O administration schedule that allows early FGF reduction. METHODS: Thirty-four ASA PS I or II patients undergoing plastic, urologic, or gynecologic surgery received desflurane in O2/N2O. In the ADU group (n = 24), an initial 3 min high FGF of O2 and N2O (2 and 4 L.min-1, respectively) was used, followed by 0.3 L.min-1 O2 + 0.4 L.min-1 N2O. The desflurane vaporizer setting (FD) was 6.5% for the first 15 min, and 5.5% during the next 25 min. In the Zeus group (n = 10), the Zeus® was used in automated closed circuit anesthesia mode with a selected end-expired (FA) desflurane target of 4.6%, and O2/N2O as the carrier gases with a target inspired O2% of 30%. Desflurane FA and consumption during the first 40 min were compared using repeated measures one-way ANOVA. RESULTS: Age and weight did not differ between the groups (P > 0.05), but patients in the Zeus group were taller (P = 0.04). In the Zeus group, the desflurane FA was lower during the first 3 min (P < 0.05), identical at 4 min (P > 0.05), and slightly higher after 4 min (P < 0.05). Desflurane consumption was higher in the Zeus group at all times, a difference that persisted after correcting for the small difference in FA between the two groups. CONCLUSION: Agent consumption with an automated closed-circuit anesthesia machine is higher than with a conventional anesthesia machine when the latter is used with a specific vaporizer-FGF sequence. Agent consumption during automated delivery might be further reduced by optimizing the algorithm(s) that manages the initial FGF or by tolerating some N2 in the circuit to minimize the need for intermittent flushing.
RESUMO
BACKGROUND: Gas chromatography (GC) has often been considered the most accurate method to measure the concentration of inhaled anesthetic vapors. However, infrared (IR) gas analysis has become the clinically preferred monitoring technique because it provides continuous data, is less expensive and more practical, and is readily available. We examined the accuracy of a modern IR analyzer (M-CAiOV compact gas IR analyzer (General Electric, Helsinki, Finland) by comparing its performance with GC. METHODS: To examine linearity, we analyzed 3 different concentrations of 3 different agents in O2: 0.3, 0.7, and 1.2% isoflurane; 0.5, 1, and 2% sevoflurane; and 1, 3, and 6% desflurane. To examine the effect of carrier gas composition, we prepared mixtures of 1% isoflurane, 1 or 2% sevoflurane, or 6% desflurane in 100% O2 (= O2 group); 30%O2+ 70%N2O (= N2O group), 28%O2 + 66%N2O + 5%CO2 (= CO2 group), or air. To examine consistency between analyzers, four different M-CAiOV analyzers were tested. RESULTS: The IR analyzer response in O2 is linear over the concentration range studied: IR isoflurane % = -0.0256 + (1.006 * GC %), R = 0.998; IR sevoflurane % = -0.008 + (0.946 * GC %), R = 0.993; and IR desflurane % = 0.256 + (0.919 * GC %), R = 0.998. The deviation from GC calculated as (100*(IR-GC)/GC), in %) ranged from -11 to 11% for the medium and higher concentrations, and from -20 to +20% for the lowest concentrations. No carrier gas effect could be detected. Individual modules differed in their accuracy (p = 0.004), with differences between analyzers mounting up to 12% of the medium and highest concentrations and up to 25% of the lowest agent concentrations. CONCLUSION: M-CAiOV compact gas IR analyzers are well compensated for carrier gas cross-sensitivity and are linear over the range of concentrations studied. IR and GC cannot be used interchangeably, because the deviations between GC and IR mount up to ± 20%, and because individual analyzers differ unpredictably in their performance.
RESUMO
STUDY OBJECTIVE: To determine whether early reduction of oxygen and nitrous oxide fresh gas flow from 6 L/min to 0.7 L/min could be accomplished while maintaining end-expired nitrous oxide concentration > or =50% with an Anesthesia Delivery Unit anesthesia machine. STUDY DESIGN: Prospective, randomized clinical study. SETTING: Large teaching hospital in Belgium. PATIENTS: 53 ASA physical status I and II patients requiring general endotracheal anesthesia and controlled mechanical ventilation. INTERVENTIONS: Patients were randomly assigned to one of 4 groups depending on the duration of high oxygen/nitrous oxide fresh gas flow (two and 4 L/min, respectively) before lowering total fresh gas flow to 0.7 L/min (0.3 and 0.4 L/min oxygen and nitrous oxide, respectively): one, two, three, or 5 minutes (1-minute group, 2-minute group, 3-minute group, and 5-minute group), with n = 10, 12, 13, and 8, respectively. The course of the end-expired nitrous oxide concentration and bellows volume deficit at end-expiration was compared among the 4 groups during the first 30 minutes. RESULTS: At the end of the high-flow period the end-expired nitrous oxide concentration was 35.6 +/- 6.2%, 48.4 +/- 4.8%, 53.7 +/- 8.7%, and 57.3 +/- 1.6% in the 4 groups, respectively. Thereafter, the end-expired nitrous oxide concentration decreased to a nadir of 36.1 +/- 4.5%, 45.4 +/- 3.8%, 50.9 +/- 6.1%, and 55.4 +/- 2.8% after three, 4, 6, and 8 minutes after flows were lowered in the 1- to 5-minute groups, respectively. A decrease in bellows volume was observed in most patients, but was most pronounced in the 2-minute group. The bellows volume deficit gradually faded within 15 to 20 minutes in all 4 groups. CONCLUSIONS: A 3-minute high-flow period (oxygen and nitrous oxide fresh gas flow of 2 and 4 L/min, respectively) suffices to attain and maintain end-expired nitrous oxide concentration > or =50% and ensures an adequate bellows volume during the ensuing low-flow period.